Drug Profile
Bevacizumab biosimilar - Pharma Research BIO
Alternative Names: BCD 500Latest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator BIOCND
- Developer Pharma Research BIO
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Jan 2020 Discontinued - Phase-III for Cancer in South Korea (Parenteral)
- 26 Jul 2017 Phase-III clinical trials in Cancer in South Korea (Parenteral) (BIOCND pipeline, July 2017)
- 16 Dec 2016 Preclinical trials in Cancer in South Korea (Parenteral), before December 2016